Aberdeen Group plc Sells 22,498 Shares of Smith & Nephew SNATS, Inc. $SNN

Aberdeen Group plc trimmed its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 15.9% in the first quarter, HoldingsChannel reports. The firm owned 118,710 shares of the medical equipment provider’s stock after selling 22,498 shares during the quarter. Aberdeen Group plc’s holdings in Smith & Nephew SNATS were worth $3,368,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Hexagon Capital Partners LLC boosted its position in Smith & Nephew SNATS by 63.3% during the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 406 shares during the period. Richards Merrill & Peterson Inc. boosted its position in Smith & Nephew SNATS by 500.0% during the first quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 1,000 shares during the period. Bessemer Group Inc. boosted its position in Smith & Nephew SNATS by 3,471.4% during the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider’s stock worth $49,000 after purchasing an additional 1,701 shares during the period. Hara Capital LLC boosted its position in Smith & Nephew SNATS by 391.4% during the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock worth $60,000 after purchasing an additional 1,957 shares during the period. Finally, Opal Wealth Advisors LLC bought a new position in Smith & Nephew SNATS during the first quarter worth $73,000. 25.64% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on SNN shares. HSBC downgraded Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Friday, April 25th. Hsbc Global Res downgraded Smith & Nephew SNATS from a “strong-buy” rating to a “hold” rating in a report on Friday, April 25th. Finally, Canaccord Genuity Group lifted their target price on Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a “hold” rating in a report on Monday. Six research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $36.00.

Smith & Nephew SNATS Stock Up 1.5%

SNN stock opened at $37.4250 on Thursday. The company has a market cap of $16.39 billion, a PE ratio of 17.33, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68. The business has a 50-day simple moving average of $31.65 and a 200 day simple moving average of $29.06. Smith & Nephew SNATS, Inc. has a 52 week low of $23.69 and a 52 week high of $37.58. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60.

Smith & Nephew SNATS Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 3rd will be paid a $0.285 dividend. This represents a yield of 210.0%. The ex-dividend date of this dividend is Friday, October 3rd. Smith & Nephew SNATS’s payout ratio is 41.20%.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.